What is the address of Dr. Axel DERWA, inwendige geneeskunde?

The registered office of Dr. Axel DERWA, inwendige geneeskunde is located at Konijnenpijp(LIN) 4, 3210 Lubbeek.

Is Dr. Axel DERWA, inwendige geneeskunde still active?

Yes. According to the CBE (18 September 2026) Dr. Axel DERWA, inwendige geneeskunde is active, legal situation “Normale toestand”, started on 22 January 2007.

Is Dr. Axel DERWA, inwendige geneeskunde registered on Peppol?

Yes, Dr. Axel DERWA, inwendige geneeskunde is registered on the Peppol network with ID 0208:0886911976.

What is the enterprise number of Dr. Axel DERWA, inwendige geneeskunde?

The enterprise number of Dr. Axel DERWA, inwendige geneeskunde is BE0886911976.

When was Dr. Axel DERWA, inwendige geneeskunde founded?

Dr. Axel DERWA, inwendige geneeskunde was founded on 22 January 2007.

Who are the directors of Dr. Axel DERWA, inwendige geneeskunde?

According to the 2025 annual accounts, the directors of Dr. Axel DERWA, inwendige geneeskunde are: Axel Derwa.

Is Dr. Axel DERWA, inwendige geneeskunde a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 22 January 2007; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Dr. Axel DERWA, inwendige geneeskunde make in 2025?

Dr. Axel DERWA, inwendige geneeskunde posted a profit after taxes of € 181,709 in financial year 2025.

What is the revenue of Dr. Axel DERWA, inwendige geneeskunde?

As a small company, Dr. Axel DERWA, inwendige geneeskunde is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 281,164.

Dr. Axel DERWA, inwendige geneeskunde (Private Limited)

Dossier Dr. Axel DERWA, inwendige geneeskunde, printed on 18 September 2026 from databakkes.be/en/0886911976/dr-axel-derwa-inwendige-geneeskunde. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Dr. Axel DERWA, inwendige geneeskunde from Lubbeek, company number BE0886911976, closed financial year 2025 with a result of € 181,709 after tax. For that financial year Dr. Axel DERWA, inwendige geneeskunde recorded a gross margin of € 281,164 and equity of € 699,513. Compared with financial year 2024, the result moved from € 115,113 to € 181,709. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.

What it is worth Growing

€ 699,513

▲ 4% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 181,709

▲ 58% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 141,157

▲ 52% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 154,352 paid out

85 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Vehicles and equipment

€ 7,874

▲ 144% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 5 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 56,533

▼ 16% vs 2024

€ 10,600 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.

Owed to suppliers

€ 2,154

▼ 70% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 28,761

▼ 60% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 117,844 Gross margin 2022: € 117,844 First fiscal year in the series	€ 186,382 Gross margin 2023: € 186,382 ▲ 58% vs 2022 (€ 117,844) Favourable step	€ 180,951 Gross margin 2024: € 180,951 ▼ 3% vs 2023 (€ 186,382) Unfavourable step	€ 281,164 Gross margin 2025: € 281,164 ▲ 55% vs 2024 (€ 180,951) Favourable step	▲ 55%
Profit after taxes	€ 84,717 Profit after taxes 2022: € 84,717 First fiscal year in the series	€ 124,132 Profit after taxes 2023: € 124,132 ▲ 47% vs 2022 (€ 84,717) Favourable step	€ 115,113 Profit after taxes 2024: € 115,113 ▼ 7% vs 2023 (€ 124,132) Unfavourable step	€ 181,709 Profit after taxes 2025: € 181,709 ▲ 58% vs 2024 (€ 115,113) Favourable step	▲ 58%
Equity	€ 662,324 Equity 2022: € 662,324 First fiscal year in the series	€ 786,456 Equity 2023: € 786,456 ▲ 19% vs 2022 (€ 662,324) Favourable step	€ 672,156 Equity 2024: € 672,156 ▼ 15% vs 2023 (€ 786,456) Unfavourable step	€ 699,513 Equity 2025: € 699,513 ▲ 4% vs 2024 (€ 672,156) Favourable step	▲ 4%
Total debts	€ 226,641 Total debts 2022: € 226,641 First fiscal year in the series	€ 163,218 Total debts 2023: € 163,218 ▼ 28% vs 2022 (€ 226,641) Favourable step	€ 147,364 Total debts 2024: € 147,364 ▼ 10% vs 2023 (€ 163,218) Favourable step	€ 89,543 Total debts 2025: € 89,543 ▼ 39% vs 2024 (€ 147,364) Favourable step	▼ 39%
Cash	€ 284,229 Cash 2022: € 284,229 First fiscal year in the series	€ 73,736 Cash 2023: € 73,736 ▼ 74% vs 2022 (€ 284,229) Unfavourable step	€ 92,677 Cash 2024: € 92,677 ▲ 26% vs 2023 (€ 73,736) Favourable step	€ 141,157 Cash 2025: € 141,157 ▲ 52% vs 2024 (€ 92,677) Favourable step	▲ 52%
Land & buildings	-	-	€ 20,368 Land & buildings 2024: € 20,368 First fiscal year in the series	€ 36,778 Land & buildings 2025: € 36,778 ▲ 81% vs 2024 (€ 20,368) Unchanged	▲ 81%
Retained profit	€ 649,924 Retained profit 2022: € 649,924 First fiscal year in the series	€ 774,056 Retained profit 2023: € 774,056 ▲ 19% vs 2022 (€ 649,924) Favourable step	€ 659,756 Retained profit 2024: € 659,756 ▼ 15% vs 2023 (€ 774,056) Unfavourable step	€ 687,113 Retained profit 2025: € 687,113 ▲ 4% vs 2024 (€ 659,756) Favourable step	▲ 4%
Dividend	€ 84,717 Dividend 2022: € 84,717 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 84,717) Unchanged	€ 229,413 Dividend 2024: € 229,413 Unchanged (€ 0) Unchanged	€ 154,352 Dividend 2025: € 154,352 ▼ 33% vs 2024 (€ 229,413) Unchanged	▼ 33%
Bank debt	€ 108,399 Bank debt 2022: € 108,399 First fiscal year in the series	€ 97,992 Bank debt 2023: € 97,992 ▼ 10% vs 2022 (€ 108,399) Favourable step	€ 67,133 Bank debt 2024: € 67,133 ▼ 31% vs 2023 (€ 97,992) Favourable step	€ 56,533 Bank debt 2025: € 56,533 ▼ 16% vs 2024 (€ 67,133) Favourable step	▼ 16%
Balance sheet total	€ 888,965 Balance sheet total 2022: € 888,965 First fiscal year in the series	€ 949,674 Balance sheet total 2023: € 949,674 ▲ 7% vs 2022 (€ 888,965) Unchanged	€ 819,520 Balance sheet total 2024: € 819,520 ▼ 14% vs 2023 (€ 949,674) Unchanged	€ 789,056 Balance sheet total 2025: € 789,056 ▼ 4% vs 2024 (€ 819,520) Unchanged	▼ 4%

Key figures of Dr. Axel DERWA, inwendige geneeskunde, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Dr. Axel DERWA, inwendige geneeskunde?

What happened at Dr. Axel DERWA, inwendige geneeskunde in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 31, 2026 New annual accounts for financial year 2025: profit of € 181,709 (▲ 58% vs 2024). filed late Source: NBB ↗
Jan 22, 2007 Start of the company according to the CBE. KBO

In short

From € 84,717 profit in 2022 to € 181,709 profit in 2025.

Paid € 204,491 in corporate taxes since 2022.

Best year ever: 2025, with € 181,709 profit.

Paid out € 468,481 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at Dr. Axel DERWA, inwendige geneeskunde? We notify you, reason included.

Follow Dr. Axel DERWA, inwendige geneeskunde

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Axel Derwa

Dr. Axel DERWA, inwendige geneeskunde

Behind Dr. Axel DERWA, inwendige geneeskunde is Axel Derwa.

See the full network in the app

Directors

According to the 2025 annual accounts

Axel Derwa

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Konijnenpijp(LIN) 4

3210 Lubbeek

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0886.911.976
VAT number: BE 0886.911.976
Registered office: Konijnenpijp(LIN) 4, 3210 Lubbeek
Names & denominations: Dr. Axel DERWA, inwendige geneeskunde
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 22 January 2007
Peppol: Active · Active since 12 Aug 2025

View on CBE Public ↗ Annual accounts (NBB) ↗